Adriamycin and cisplatin in the treatment of stage III and IV epithelial ovarian carcinoma
- 18 February 1988
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 29 (2), 208-221
- https://doi.org/10.1016/0090-8258(88)90215-6
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Nonparametric Estimation from Incomplete ObservationsPublished by Springer Nature ,1992
- Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: A randomized clinical trialCancer Chemotherapy and Pharmacology, 1985
- Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdensCancer, 1983
- A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinomaCancer, 1983
- Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycinCancer, 1981
- Radiation therapy in stage II ovarian carcinoma. The influence of histologic gradeCancer, 1980
- Advanced ovarian cancer correlation of histologic grade with response to therapy and survivalCancer, 1980
- PHASE-2 STUDY OF CIS-DICHLORODIAMMINEPLATINUM(II) (NSC-119875) IN ADVANCED ADENOCARCINOMA OF OVARY1976
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958